Chemomab Therapeutics (NASDAQ:CMMB) Price Target Raised to $7.00 at Maxim Group

Chemomab Therapeutics (NASDAQ:CMMB) had its price objective boosted by Maxim Group from $4.00 to $7.00 in a research note issued to investors on Thursday,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Separately, Oppenheimer reiterated an “outperform” rating and set a $11.00 target price (down from $13.00) on shares of Chemomab Therapeutics in a research report on Friday, November 15th.

Chemomab Therapeutics Price Performance

NASDAQ:CMMB opened at $1.77 on Thursday. The firm’s 50 day simple moving average is $1.97 and its 200 day simple moving average is $1.70. Chemomab Therapeutics has a one year low of $0.58 and a one year high of $2.55. The company has a market cap of $25.42 million, a PE ratio of -1.77 and a beta of 0.66.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in Chemomab Therapeutics during the 4th quarter worth approximately $26,000. XTX Topco Ltd raised its holdings in Chemomab Therapeutics by 63.8% during the 4th quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock worth $45,000 after purchasing an additional 9,706 shares during the last quarter. Finally, Sphera Funds Management LTD. bought a new position in Chemomab Therapeutics during the 3rd quarter worth approximately $1,907,000. Institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).